Excision BioTherapeutics Initiates Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

EBT-101 is a CRISPR-based therapeutic being developed as a potential functional cure for people living with HIVFirst-in-human trial is now open for enrollment SAN FRANCISCO, Jan. 27, 2022 (GLOBE NEWSWIRE)

Related Keywords

California ,United States ,San Francisco ,Robert Flamm ,Kostenloser Wertpapierhandel ,Lisa Danzig ,Daniel Dornbusch ,John Fraunces ,Rachelm Presti ,Excision Biotherapeutics Inc ,Loreda Holdings ,Burns Mcclellan Inc ,Temple University ,Chief Executive Officer ,Chief Medical Officer ,Associate Professor ,Washington University School ,Principal Investigator ,Greatpoint Ventures ,Norwest Venture Partners ,Adjuvant Capital ,Cota Capital ,Celesta Capital ,Indusage Partners ,Olive Tree ,Anzu Partners ,Silverridge Venture Partners ,Oakhouse Ventures ,Excision ,Iotherapeutics ,Nitiates ,Hase ,Trial ,Valuating ,Potential ,Cure ,